The Growing Prevalence Of Neurological Disorders Drives The Growth Of The Market Due To Increasing Incidence Of Age-Related Conditions Is Supporting Development Across The Multiple Sclerosis Treatment Market

The Business Research Company’s 2026 market reports feature advanced enhancements such as market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, delivering more actionable and strategically valuable research.

How Will The Market Value Of The Multiple Sclerosis Treatment Market Increase Between 2026 And 2030?

The multiple sclerosis treatment market size has seen robust growth over recent years. It is anticipated to expand from $26.13 billion in 2025 to $27.44 billion in 2026, achieving a compound annual growth rate (CAGR) of 5.0%. The expansion observed historically can be credited to advances in autoimmune disease research, the availability of injectable MS therapies, the increase in neurology clinic facilities, hospital-based treatment options, and the progress in biologics development.

The multiple sclerosis treatment market is projected to experience consistent expansion over the upcoming years. It is anticipated to reach $33.02 billion by 2030, demonstrating a compound annual growth rate (CAGR) of 4.7%. This forecasted growth can be linked to factors such as the increasing acceptance of oral therapies, the rise of home-based MS care, improved long-term disease management, advancements in imaging diagnostics, and the development of personalized immunotherapy. Key trends influencing this period encompass the broadening range of disease-modifying therapies, the proliferation of oral MS medications, a greater emphasis on early diagnosis, increased utilization of monoclonal antibodies, and the development of customized treatment plans.

Download A Free Sample Report For Comprehensive Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=24612&type=smp

What Important Drivers Are Powering The Multiple Sclerosis Treatment Market Growth?

The expansion of the multiple sclerosis treatment market is anticipated to be significantly driven by the increasing incidence of neurological disorders. These disorders are medical conditions impacting the brain, spinal cord, and the entire nervous system, resulting in challenges with movement, speech, behavior, or fundamental bodily functions. The uptick in neurological disorders can be attributed to an aging global population, where extended lifespans elevate the likelihood of developing age-related illnesses such as Alzheimer’s. Multiple sclerosis treatment provides assistance in managing neurological conditions through modulating the immune system, thereby reducing inflammation, preventing neural damage, and easing symptoms, ultimately enhancing patients’ quality of life. For example, data from October 2023, published by the World Federation of Neurology, a UK-based association representing national neurological societies, indicates that over 40% of the worldwide populace currently lives with some type of neurological condition, with this impact projected to almost double by 2050. Consequently, the rising occurrence of neurological disorders is a key factor fueling the growth of the multiple sclerosis treatment market.

How Does Segment Analysis Break Down The Multiple Sclerosis Treatment Market Structure?

The multiple sclerosis treatment market covered in this report is segmented –

1) By Treatment Type: Immunomodulators, Corticosteroids, Symptomatic Treatments, Monoclonal Antibodies, Oral Therapies

2) By DiseaseType: Clinically Isolated Syndrome, Relapse-Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis

3) By Route Of Administration: Oral, Injectable, Intravenous

4) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Online Pharmacies

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End-Users

Subsegments:

1) By Immunomodulators: Interferon Beta-1A, Interferon Beta-1B, Glatiramer Acetate

2) By Corticosteroids: Methylprednisolone, Prednisone, Dexamethasone

3) By Symptomatic Treatments: Muscle Relaxants, Antidepressants, Anticonvulsants, Bladder Dysfunction Drugs

4) By Monoclonal Antibodies: Natalizumab, Ocrelizumab, Alemtuzumab, Ofatumumab

5) By Oral Therapies: Fingolimod, Dimethyl Fumarate, Teriflunomide, Cladribine, Siponimod

What Trends Are Influencing The Multiple Sclerosis Treatment Market Outlook?

Leading companies in the multiple sclerosis treatment market are developing advanced therapies, such as monoclonal antibody drugs, to enhance their effectiveness and improve patient outcomes. Monoclonal antibody drugs are laboratory-created molecules designed to target specific antigens, and in multiple sclerosis, they function by reducing inflammation and preventing immune cells from attacking nerve fibers, thereby managing disease progression. For instance, in February 2024, Roche Pharma India, an India-based pharmaceutical company, launched Ocrevus (Ocrelizumab) for the treatment of multiple sclerosis (MS). This drug specifically targets CD20-positive B cells, aiding in the reduction of inflammation and nerve damage in MS. It is the first therapy approved for both relapsing and primary progressive forms of MS, substantially decreasing relapse rates and slowing the progression of disability with the convenience of twice-yearly infusions.

Which Firms Are Competing In The Multiple Sclerosis Treatment Market?

Major companies operating in the multiple sclerosis treatment market are Biogen Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Bayer AG, Teva Pharmaceutical Industries Ltd, Sanofi Genzyme, Merck KGaA, Bristol Myers Squibb, AbbVie Inc., Johnson & Johnson (Janssen), TG Therapeutics Inc., Acorda Therapeutics Inc., Takeda Pharmaceutical Company Ltd, Mitsubishi Tanabe Pharma Corporation, Chugai Pharmaceutical Co. Ltd., Pfizer Inc., Almirall S.A., Otsuka Pharmaceutical Co. Ltd., Apitope International NV, BrainStorm Cell Therapeutics Inc., Roche Diagnostics, InnoCare Pharma, NervGen Pharma Corp., Receptos Inc., Biogen Idec International GmbH, MedDay Pharmaceuticals SA, Genentech Inc., Roche Holding AG

Access The Complete Multiple Sclerosis Treatment Market Report:

https://www.thebusinessresearchcompany.com/report/multiple-sclerosis-treatment-global-market-report

Which Region Is The Primary Market For The Multiple Sclerosis Treatment Market?

North America was the largest region in the multiple sclerosis treatment market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the multiple sclerosis treatment market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Access Multiple Sclerosis Treatment Market Report for Deeper Competitive Insights

https://www.thebusinessresearchcompany.com/sample.aspx?id=24612&type=smp

Browse Through More Reports Similar to the Global Multiple Sclerosis Treatment Market 2026, By The Business Research Company

Rare Neurological Disease Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/rare-neurological-disease-treatment-global-market-report

Neuralgia Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/neuralgia-treatment-global-market-report

Progressive Multifocal Leukoencephalopathy Treatment Market Report 2026

https://www.thebusinessresearchcompany.com/report/progressive-multifocal-leukoencephalopathy-treatment-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas: +1 310-496-7795